NAV

Piribedil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Piribedil is a dopamine agonist used with or without levodopa in the treatment of Parkinson's disease.

Generic Name
Piribedil
DrugBank Accession Number
DB12478
Background

Piribedil has been investigated in Parkinson's Disease.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 298.346
Monoisotopic: 298.142975836
Chemical Formula
C16H18N4O2
Synonyms
  • Piribedil
External IDs
  • ET-495
  • EU-4200
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofParkinson's disease (pd)•••••••••••••••••••••• ••••••• •••••••• •••••••
Used in combination to treatParkinson's disease (pd)Regimen in combination with: Levodopa (DB01235)•••••••••••••••••••••• ••••••• •••••••• •••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDopamine D2 receptorNot AvailableHumans
UDopamine D3 receptorNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetophenazineThe therapeutic efficacy of Piribedil can be decreased when used in combination with Acetophenazine.
AmisulprideThe therapeutic efficacy of Piribedil can be decreased when used in combination with Amisulpride.
AmoxapineThe therapeutic efficacy of Piribedil can be decreased when used in combination with Amoxapine.
ApomorphineThe risk or severity of adverse effects can be decreased when Apomorphine is combined with Piribedil.
AripiprazoleThe risk or severity of adverse effects can be decreased when Aripiprazole is combined with Piribedil.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
N04BC08 — Piribedil
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Benzodioxoles / Dialkylarylamines / N-alkylpiperazines / Aralkylamines / Aminopyrimidines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds
show 3 more
Substituents
Acetal / Amine / Aminopyrimidine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzodioxole / Dialkylarylamine / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
DO22K1PRDJ
CAS number
3605-01-4
InChI Key
OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2
IUPAC Name
2-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}pyrimidine
SMILES
C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1

References

General References
  1. FDA Thailand Product Information: Trivastal (piribedil) extended-release tablets [Link]
  2. TITCK Product Information: Trivatal (piribedil) extended-release tablets [Link]
PubChem Compound
4850
PubChem Substance
347828716
ChemSpider
4684
BindingDB
85092
RxNav
8353
ChEBI
92833
ChEMBL
CHEMBL1371770
ZINC
ZINC000019537374
Wikipedia
Piribedil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentIdiopathic Parkinson's Disease1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)3
Not AvailableCompletedTreatmentTinnitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral50 mg
Tablet, extended releaseOral50 mg
Tablet, film coated, extended releaseOral
Tablet, film coatedOral50 mg
Tablet, coatedOral20 MG
Tablet, extended releaseOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.57 mg/mLALOGPS
logP1.56ALOGPS
logP2.03Chemaxon
logS-2.3ALOGPS
pKa (Strongest Basic)6.53Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area50.72 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity83.53 m3·mol-1Chemaxon
Polarizability31.87 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1930000000-45b06a981c7ebf1054da
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-e783ad59150ac94e2186
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-dd79ad935850aa39efa4
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014j-0090000000-131e1c81f4d54b493b1d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014j-0090000000-5892eeb7f502fbe45125
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0079-0930000000-da060dce86d616107ab9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00ls-0890000000-b380c44c760b85343311
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-179.9663801
predicted
DarkChem Lite v0.1.0
[M-H]-166.80971
predicted
DeepCCS 1.0 (2019)
[M+H]+181.0296801
predicted
DarkChem Lite v0.1.0
[M+H]+169.16771
predicted
DeepCCS 1.0 (2019)
[M+Na]+175.26086
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Dopamine D2 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [Article]
Details2. Dopamine D3 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [Article]

Drug created at October 20, 2016 22:32 / Updated at May 29, 2021 18:11